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Abstract
Background: End-of-life policies are hotly debated in many countries, with international evidence frequently
used to support or oppose legal reforms. Existing reviews are limited by their focus on specific practices or
selected jurisdictions. The objective is to review international time trends in end-of-life practices.
Methods: We conducted a systematic review of empirical studies on medical end-of-life practices, including
treatment withdrawal, the use of drugs for symptom management, and the intentional use of lethal drugs.
A search strategy was conducted in MEDLINE, EMBASE, Web of Science, Sociological Abstracts, PAIS
International, Worldwide Political Science Abstracts, International Bibliography of the Social Sciences and
CINAHL. We included studies that described physicians’ actual practices and estimated annual frequency
at the jurisdictional level. End-of-life practice frequencies were analyzed for variations over time, using
logit regression.
Results: Among 8183 references, 39 jurisdiction-wide surveys conducted between 1990 and 2010 were
identified. Of those, 22 surveys used sufficiently similar research methods to allow further statistical analysis.
Significant differences were found across surveys in the frequency of treatment withdrawal, use of opiates
or sedatives and the intentional use of lethal drugs (X2 > 1000, p < 0.001 for all). Regression analyses showed
increased use of opiates and sedatives over time (p < 0.001), which could reflect more intense symptom
management at the end of life, or increase in these drugs to intentionally cause patients’ death.
Conclusion: The use of opiates and sedatives appears to have significantly increased over time between
1990 and 2010. Better distinction between practices with different legal status is required to properly
interpret the policy significance of these changes. Research on the effects of public policies should
take a comprehensive look at trends in end-of-life practice patterns and their associations with policy
changes.
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Background
End-of-life policies are hotly debated in many countries,
with international evidence used to support or oppose
legal reforms [1–3]. For example, recent policy proposals
on the legalization of “medical aid in dying”, “physician-
assisted suicide” and “euthanasia” in Canada, the United
Kingdom, and France have made frequent references to
empirical research from other countries [4, 5].
A scoping review highlighted the need to take a com-
prehensive look at international end-of-life practice vari-
ations, because existing reviews tended to focus on
specific practices or selected countries [6]. More specif-
ically, trends in patterns of “euthanasia” and “assisted
suicide” are most frequently discussed, with less atten-
tion being put on treatment withdrawal and the use of
drugs for symptom management [7–11]. This could be
problematic as it limits the ability to study the effects of
public policies on the full range of end-of-life practices.
Also, changes in a single jurisdiction might reflect
global trends in end-of-life practices, rather than do-
mestic patterns.
Objective
The goal of this research was to systematically review
international time trends in end-of-life practices.
Methods
Design
We conducted a systematic review of empirical stud-
ies on medical end-of-life practices (see Fig. 1 for the
flowchart).
Definitions and classification of end-of-life practices
Definitions and labelling of medical end-of-life prac-
tices vary and no consensus exists on terminology at
the international level. For example, definitions of
Fig. 1 Flowchart of study inclusion and exclusion
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“euthanasia” have evolved over time and across juris-
dictions [12, 13]. For these reasons, we developed a
descriptive classification of medical end-of-life prac-
tices. The classification is based on observable med-
ical behaviors that can be studied empirically, and
distinguishes practices with different legal status across
jurisdictions, including:
1. Withdrawing or withholding of treatments that have
the potential to prolong life;
2. Use of drugs for symptom management even if
an unintended side-effect may be to shorten life;
3. Intentional use of a lethal drug.
The classification further distinguishes whether end-
of-life practices are carried out: a) with a voluntary and
informed request made by the patient; b) with a volun-
tary advanced directive made by a previously compe-
tent patient, c) with a substitute request by the proxy
decision-maker of an incompetent patient; or d) with-
out a patient or substitute request. We also distinguish
whether lethal drugs are administered by patients or by
someone else.
Testing of this classification in a scoping review
allowed for the translation of different end-of-life prac-
tice definitions into comparable categories, despite varia-
tions in labeling and definitions used in the original
studies [6].
Inclusion criteria
To be included, articles written in English or French
needed to: 1) report on physicians’ actual end-of-life
practices (rather than their opinions and attitudes);
2) include data on treatment withholding/withdrawal,
use of drugs for symptom management, and the
intentional use of lethal drugs; 3) allow estimates of
annual practice frequency at the jurisdictional level.
We excluded articles limited to specific populations
(e.g. neonates) or practice settings (e.g. nursing
homes). We also excluded articles using physicians’
self-reporting of end-of-life practices to public regu-
latory authorities (e.g. euthanasia review committees)
as this data source would not allow comparisons
across jurisdictions with different legislative frame-
works and would not provide information on some
categories of practices included in our classification
(e.g. intentional use of lethal drugs without patient
request).
Search strategy
The literature databases searched were: MEDLINE,
Embase, PsycInfo, Web of Science (SCI, SSCI),
Sociological Abstracts, EMBASE, PAIS International,
Worldwide Political Science Abstracts, International
Bibliography of the Social Sciences and CINAHL.
Search terms are listed in Appendix 1. The litera-
ture was searched in April 2014 and were pooled
with articles identified in a previous scoping review
that also included grey literature and online publica-
tions [6].
Data screening and extraction
Two reviewers separately screened each article and
any discrepancies regarding the inclusion or exclusion
of articles were resolved in team meetings. The infor-
mation and statistics on these articles were extracted
by one of two assistants and two review authors,
verified by one of the review authors (GG or YSC),
and entered in a FileMaker Pro v. 13 database devel-
oped with an information technology specialist. The
items extracted from articles included year of publi-
cation, authors, title, abstract, source database, the
types of end-of-life practice studied, funding sources,
types of study (qualitative, quantitative or mixed),
characteristics of study participants, and affiliations of
first authors. When the same survey was reported in
multiple articles, an index article was used to extract
information on data collection methods (including
duration, population groups and region of study), re-
sponse rates, selective reporting for outcomes, details
in statistical procedures, total numbers of deaths and
summary percentages of end-of-life practices in each
jurisdiction.
Comparability of study methods and risk of bias
The objectives for assessing the risk of bias were to
1) identify the risk of bias in estimated frequencies;
2) understand the heterogeneity of study methods to
identify a subset of comparable studies using similar
reference populations and outcome measures. We
used quality appraisal criteria designed for systematic
reviews [14, 15] and observational studies [16, 17].
The assessment criteria were: background information
(population coverage, number of studied deaths, total
number of deaths in the jurisdiction) [18]; basic sur-
vey information (article types, study design, author
affiliations) [16]; design-specific assessment (statis-
tical, conflict of interest, response rate, frequency of
measurement, sample sizes, methods to adjust for se-
lection bias) [19–21]; and practice-related assessment
(methods for measuring outcome variables and se-
lective outcome reporting) [22]. After reviewing the
included surveys, the comparability of study design
and statistical methods were assessed in the team
meetings. Surveys using comparable methods (popu-
lation characteristics, questionnaire types, statistical
methods, and reporting methods) were retained for
regression analysis.
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Data analysis
The main outcome measure was the annual fre-
quency of end-of-life practices as a percentage (%) of
all deaths [7]. We further collected the 95 % confi-
dence intervals (CIs) of the weighted frequencies or
the nominators and denominators of the reported
frequencies.
The extracted data were analyzed with R programming
languange and RStudio (version 0.98.1091, RStudio Inc.).
The surveys that adopted multiple-stage sampling usu-
ally provided the mean percentages of end-of-life prac-
tice with 95 % CIs. The comparisons of the percentages
of end-of-life practices across jurisdictions were carried
out using Chi-squared tests. If Chi-squared tests were
not appropriate, simulation was used [23].
The relationships between the frequencies of end-
of-life practices and time (year of data collection)
were assumed to be linear and were analyzed with
logit regression. The null hypotheses were that there
were no associations between the frequencies and
time (regression coefficients of time equal to zero).
Jurisdictions or survey types that were found to be
significantly associated with different levels of end-
of-life practice frequencies [7] were adjusted in
models that included all eligible surveys. Due to the
variability originating from stratified sampling and
adjustment for non-response, the 95 % CIs of re-
ported frequencies were taken into account using
simulations. The mean percentages were used to
draw the regression lines in the graphs. The magni-
tudes of change in end-of-life practices from all in-
cluded surveys were estimated with the differences
in the predicted frequencies of the Dutch death cer-
tificate surveys from 1990 (or 2001 for use of seda-
tives for symptom management) to 2010 based on
the regression models that included all surveys, since
the Dutch surveys were the only ones to have been
implemented throughout the period. The Dutch and
Belgian surveys were also analyzed with separate re-
gression models.
Results
Among 8183 references, 39 jurisdiction-wide surveys
were identified. Of those, 22 surveys used suffi-
ciently similar research methods to allow further
statistical analysis and comparisons (Appendix 2).
Response rates ranged from 40.0 to 84.0 % (median:
65.9 %). The 22 included surveys adopted or modi-
fied questionnaires that were developed in the
Netherlands in the early 1990s [24] and used similar
definitions of end-of-life practices, survey methods,
and statistical analysis. Two main sampling strategies
were used to identify responding physicians: random
sampling of death certificates, and the use of
physician registries. In these surveys, physicians were
either interviewed individually or responded to self-
administered questionnaires.
Figures 2, 3, 4, 5, 6 and 7 present end-of-life practice
frequencies by year. The original studies did not allow to
fully distinguishing end-of-life practices according to
their legal status, as per our descriptive classification
(Table 1). For example, original studies did not distin-
guish treatment withdrawal with or without voluntary
patient request. Also, the use of opiates and sedatives
did not distinguish whether these drugs were adjusted to
symptom management or used with the intention to
cause death.
Treatment withholding/withdrawal and the use of
drugs for symptom management were the most frequent
end-of-life practices. The intentional use of lethal drugs
was less frequent, with frequency consistently below 5 %
of all deaths.
The total predicted percentages of death in which
physicians reported having made an end-of-life deci-
sion increased from 38.0 to 64.9 % between 1990 and
2010. Significant changes were found in the frequency
of all end-of-life practices over time (p < 0.001 for all).
The magnitude of change in the predicted frequencies
of end-of-life practices was greater for the use of opi-
oids (+15.27 % in annual practice frequency between
1990 to 2010) and for the use of sedatives with pos-
sible life-shortening effects (+6.78 %). Changes in fre-
quencies were smaller for treatment withholding or
withdrawal (−0.73 %), and for the intentional use of
lethal drugs self-administered by patients (−0.17 %),
administered by professionals with patient request
(+0.71 %), or administered by professionals without
patient request (−0.65 %). Changes in opioid use were
significantly correlated with changes in: the use of
sedatives, in the intentional use of lethal drugs ad-
ministered by patients, and in the intentional use of
lethal drugs without patient request (p < 0.05). Time
trends estimated from Dutch or Belgian data showed
the same directions of change as those predicted from
all jurisdictions, except for withholding or withdrawal
of treatment (p < 0.001).
Discussion
Key findings
To the best of our knowledge, this is the first system-
atic review to take a comprehensive look at inter-
national variations in end-of-life practices over time
from 1990 to 2010. This review showed an increase
in the frequency of cases where physicians reported
having made a decision that may have influenced the
timing of death, which is consistent with previous
findings [11]. A unique contribution of this review is
its documentation of a significant increase in the use
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of opiates and sedatives over time, as opposed to
other end-of-life practices.
The way opiate and sedative use is categorized in
the original studies makes it difficult to interpret
these time trends, because study questionnaires do
not clearly distinguish the use of opiates and sedatives
with or without the intention to hasten death [24].
For example, practices labeled in original studies as
“intensification of symptom alleviation” include the
use of drugs with a partial intention to hasten death
[25–27]. Accordingly, the observed increase in the
use of opiates and sedatives could mean that physi-
cians are becoming more prone to use these drugs
for symptom management. It may also reflect increas-
ingly using opiates and sedatives with the intention of
hastening patients’ death among physicians. The ob-
servation that the use of opiates with possible life-
shortening effects is negatively correlated with the
intentional use of lethal drugs could support the hy-
pothesis of a “substitution effect” between different
end-of-life practices. This suggests that drugs clearly
associated with an intention to hasten death (e.g.
neuromuscular blockers) are being replaced by opiates
and sedatives in situations where the use of lethal
drug is more difficult to justify in legal terms. Alter-
natively, these trends could simply reflect more pro-
fessional willingness and patients’ expectations to
treat pain and symptoms at the end-of-life. Use of
these drugs could have become more strongly em-
bedded in clinical and social practices as more in-
formation becomes available about the beneficial use
of opiates and sedatives for symptom management
[28].
Policy and research implications
This review highlights the importance of exploring
the potential effects of public policies on all end-of-
life practices, rather than focusing exclusively on
those targeted in policy documents. For example, a
number of studies have explored the relationship be-
tween “euthanasia” legalization in the Netherlands
and Belgium and the use of lethal drugs with the ex-
plicit intention to hasten death [29, 30]. However,
the review shows that the magnitude of predicted
changes in intentional use of lethal drugs is much
less than the use of opioids or sedatives with pos-
sible life-shortening effects. Focusing on small
changes in the frequencies of intentional use of
Fig. 2 Withholding or withdrawal of treatment with the potential to prolong life. Note: CI = confidence interval; United Kingdom = UK.
X2 = 36833 (null hypothesis: all frequencies the same); p < 0.001. The coefficient of year = −0.002, p < 0.001 among all surveys; greater
than zero suggesting positive changes from 1990 to 2010, lower suggesting the opposite. The coefficient of year = −0.0045, p < 0.001
among Dutch surveys only. The coefficient of year = 0.0161, p < 0.001 among Belgian surveys only. See Appendix 3 for regression
coefficients
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Fig. 3 Use of opiates with possible life-shortening effects. Note: See Fig. 2 for abbreviations. X2 = 37199 (null hypothesis: all frequencies the same),
p < 0.001. Thecoefficient of year = 0.0440, p < 0.001 among all surveys; greater than zero suggesting positive changes from 1990 to 2010, lower sug-
gesting the opposite). The coefficient of year = 0.0454, p < 0.001 among Dutch surveys. The coefficient of year = 0.0513, p < 0.001 among Belgian
surveys. See Appendix 3 for regression coefficients
Fig. 4 Use of sedatives with possible life-shortening effects. Note: See Fig. 2 for abbreviations. X2 = 19410 (null hypothesis: all frequencies the
same), p < 0.001. The coefficient of year = 0.1006, p < 0.001 among all surveys; greater than zero suggesting positive changes from 1990 to 2010,
lower suggesting the opposite. The coefficient of year = 0.0974, p < 0.001 among Dutch surveys. The coefficient of year = 0.1162, p < 0.001 among
Belgian surveys. See Appendix 3 for regression coefficients
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Fig. 5 Intentional use of lethal drugs self-administered by patients. Note: See Fig. 2 for abbreviations. X2 = 1716 (null hypothesis: all freqiuencies
the same), p < 0.001. The coefficient of year = −0.0492, p < 0.001 among all surveys; greater than zero suggesting positive changes from 1990 to
2010, lower suggesting the opposite. The coefficient of year = −0.0442, p < 0.001 among Dutch surveys. The coefficient of year = − 0.2291,
p < 0.001 among Belgian surveys. See Appendix 3 for regression coefficients
Fig. 6 Intentional use of lethal drugs administered by professionals with patient request. Note: See Fig. 2 for abbreviations. X2 = 8678 (null hypothesis:
all frequencies the same), p < 0.001 (simulated). The coefficient of year = 0.0159, p < 0.001 among all surveys; greater than zero suggesting positive
changes from 1990 to 2010, lower suggesting the opposite). The coefficient of year = 0.0142, p < 0.001 among Dutch surveys. The coefficient of
year = 0.0730, p < 0.001 among Belgian surveys. See Appendix 3 for regression coefficients
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lethal drugs risks overlooking the greater potential
impact on the use of opiates and sedatives in end-
of-life care.
This review also highlights the need for better ar-
ticulation between end-of-life research and policy.
The current confusion in empirical research between
the use of opiates and sedatives with or without the
intention to hasten death makes it difficult to inter-
pret changing patterns in the use of these drugs be-
cause practices with different legal status are grouped
together [6]. Better alignment between end-of-life
practice classification in policy documents and empir-
ical research would facilitate testing of policy-relevant
hypotheses about the potential impacts of different
policies on end-of-life practices. Our findings also
underscore the importance of international research
collaborations to harmonize study methods. Such col-
laborations have emerged in Europe (e.g. the EURELD
consortium [31]), but are less developed in North
America and elsewhere, which limits the potential for
international comparisons.
Strengths and limitations
A strength of this review is the exhaustive efforts
made to synthesize international evidence on a range
of end-of-life practices. This approach offers a com-
plementary perspective to previous reviews that fo-
cused on a single practice or a specific jurisdiction
[7, 10, 29, 32]. The use of a descriptive classification
of end-of-life practices is a novel approach to sys-
tematically review evidence on end-of-life practice,
and helped deal with international variations in la-
beling and definitions. This descriptive classification
also clarifies areas of potential confusion when prac-
tices with different legal status were grouped to-
gether in original studies. Variations due to sampling
and weighting procedures were also taken into ac-
count in the statistical analysis of end-of-life practice
frequency. This is an improvement upon previous re-
views that did not conduct statistical tests at all, or
neglected the sampling variability of reported fre-
quencies [7].
There are several limitations in this review. We
only search for studies published in English and
French. The increase in opioid use may result from
both the intent to manage symptoms and to hasten
death and we do not have evidence to assess this re-
lationship. We found that comparative international
evidence is limited by differences in study methods,
end-of-life practice definitions, data collection
Fig. 7 Intentional use of lethal drugs administered by professionals without patient request. Note: See Fig. 2 for abbreviations. X2 = 17372
(null hypothesis: all frequencies the same), p < 0.001 (simulated). The coefficient of year = −0.0574, p < 0.001 among all surveys; greater
than zero suggesting positive changes from 1990 to 2010, lower suggesting the opposite). The coefficient of year = −0.0496, p < 0.001
among Dutch surveys. The coefficient of year = −0.0924, p < 0.001 among Belgian surveys. See Appendix 3 for regression coefficients
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approaches, sampling strategies, response rates, and
target patient and professional groups. A limited
number of surveys used similar methods allowing
comparisons across jurisdictions and over time.
Nonetheless, some degree of heterogeneity remains
in the included surveys. For example, the two United
Kingdom studies included surveyed different phys-
ician groups and used different versions of the same
questionnaire [33, 34]. Other European surveys also
excluded children under one years old [31] or drew
their sample from a specific region (e.g. Flanders in
Belgium) [35]. As a result, some of the observed
international variations may still reflect differences
in study methods rather than actual differences in
practice frequency. Also, only a limited number of
European jurisdictions have conducted repeated sur-
veys over time. Accordingly, regression models are
largely driven by data from the Netherlands and
Belgium, and observed time trends may be less
generalizable to other jurisdictions. The lack of stud-
ies in other jurisdictions, such as the United States
and Canada may also limit the generalizability of
ther results.
Conclusions
The use of opiates and sedatives with possible life-
shortening effects appears to have significantly increased
over time from 1990 to 2010. Treatment withholding/
withdrawal and the use of drugs for symptom manage-
ment are the most frequent end-of-life practices. The
intentional use of lethal drugs is less frequent, with
frequency consistently below 5 % of all deaths. Better
distinction between practices with different legal status
is required to properly interpret the policy significance
of these changes. Research on the effects of public pol-
icies should take a comprehensive look at changing the
end-of-life practice patterns, rather than focus on a lim-
ited range of practices.
Table 1 Relationship between systematic review classification and original studies
Figure
number
Systematic review classification Example of labelling and definitions used in original study
2 Witholding or withdrawal of treatment with the
potential to prolong life
« Non-treatment decisions »: the withholding or withdrawal of treatment in
situations where the treatment would probably have prolonged life [24]; withhold
or withdraw medical treatment while taking into account the possibility or certainty
that this would hasten the patient’s death or with the explicit intention of hastening
the patient’s death [31]; withheld or withdrawn medical treatment while taking into
account the possible hastening of death (only for cases in which there was no single
most explicit intention, the administration of drugs prevailed over the withholding
or withdrawing of treatment) [36]. Note : Inconsistently report whether drugs were
administered with or without patient voluntary request.
3 Use of opiates with possible life-shortening effects « Alleviation of pain and symptoms » : alleviation of pain and symptoms with
opioids in such dosages that the patient’s life might have been shortened [24];
intensify the alleviation of pain and suffering while taking into account the
possibility or certainty that this would hasten the patient’s death or partly with the
intention of hastening the patient’s death [31]. Note : includes cases where opioids
were used with the intention to hasten death. Inconsistently report whether drugs were
administered with or without patient voluntary request.
4 Use of sedatives with possible life-shortening effects « Continuous deep sedation »: deeply and continuously sedated until death [36];
the patient receive drugs, such as barbiturates or benzodiazepines, to keep him/her
continuously in deep sedation or coma until death [26]. Note : does not distinguish
whether sedatives were used with or without the intention to hasten death. Inconsistently
report whether drugs were administered with or without patient voluntary request.
5 Intentional use of lethal drugs self-administered by
patients
« Assisted suicide »: the prescription or supply of drugs by a physician with the
explicit intention of shortening life, when the drug is administered by patients
[24, 31]. Note : does not include the use of drugs with the « partial » intention to
cause death.
6 Intentional use of lethal drugs administered by
professionals with patient request
« Euthanasia »: the prescription, supply or administration of drugs with the explicit
intention of shortening life, when the dru gis administered by professionals [24];
death as the result of the administration, supply, or prescription of drugs with the
explicit intention of hastening the patient’s death (administered by professionals) [31].
Note : does not include the use of drugs with the « partial » intention to cause death.
7 Intentional use of lethal drugs administered by
professionals without patient request
« Termination of life without a patient request »: the prescription, supply or
administration of drugs with the explicit intention of shortening life (without
patient explicit request) [24]; death as the result of the administration, supply, or
prescription of drugs with the explicit intention of hastening the patient’s death
(without patient explicit request) [31]. Note : does not include the use of drugs with
the « partial » intention to cause death.
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Appendix 1
Table 2 The search terms for each academic database
PubMed Embase PsycInfo Web of Science
(SCI, SSCI)
CINAHL International
Bibliography of
the Social
Sciences
Sociological
abstracts
PAIS International Worldwide Political
Science Abstracts
Euthanasia Euthanasia[MAJR:NOEXP]
OR Euthanasia,
active[MAJR:NOEXP] OR
Euthanasia, Active,
Voluntary[MAJR] OR
Suicide, assisted[MAJR]
OR Deep sedation[MAJR]
OR Euthanasia*[TI] OR
Assisted suicide*[TI] OR
Assisted death*[TI] OR
Assisted dying[TI] OR
"Aid in dying" [TI] OR
"Termination of life"[TI]
OR Shorten life[TI] or
Shortens life[TI] or Life
Shorten*[TI] or Mercy
killing[TI] OR ("End of
life"[TI] AND (Decision*[TI]
OR Practice*[TI])) OR Lethal
drug*[TI] OR Deep
sedation[TI] OR
Continuous sedation[TI]
OR Terminal sedation[TI]
*Euthanasia/or *Active
euthanasia/or
*Voluntary
euthanasia/OR
*Assisted suicide/OR
*Deep sedation/or
(Euthanasia? OR
(Assisted adj2
(Suicide? OR Death?
OR Dying)) or "Aid
in dying" OR
((Termination or
Shorten*) adj2 Life)
or Mercy killing OR
("End of life" adj2
(Decision? OR
Practice?)) OR Lethal
drug? OR ((Deep or
Continuous or
Terminal) adj2
Sedation)).ti
*Euthanasia/or
*Assisted Suicide/or
(Euthanasia? OR
(Assisted adj2
(Suicide? OR Death?
OR Dying)) or "Aid
in dying" OR
((Termination or
Shorten*) adj2 Life)
or Mercy killing OR
("End of life" adj2
(Decision? OR
Practice?)) OR Lethal
drug? OR ((Deep or
Continuous or
Terminal) adj2
Sedation)).ti
TI = (Euthanasia* OR
(Assisted NEAR/2
(Suicide? OR Death?
OR Dying)) OR "Aid
in dying" OR "Mercy
killing" OR (Life
NEAR/2 (Shorten*
or Termination))
OR ("End of life"
NEAR/2 (Decision?
OR Practice?)) OR
"Lethal drug*" OR
(Sedation NEAR/2
(Deep OR
Continuous
OR Terminal)))
MM "Euthanasia"
OR MM "Suicide,
Assisted" OR TI
(Euthanasia*
OR (Assisted N2
(Suicide? OR Death?
OR Dying)) OR "Aid
in dying" OR "Mercy
killing" OR (Life N2
(Shorten* or
Termination)) OR
("End of life" N2
(Decision? OR
Practice?)) OR
"Lethal drug*" OR
(Sedation N2 (Deep
OR Continuous
OR Terminal)))
TI,SU(Euthanasia*
OR (Assisted
NEAR/2 (Suicide*
OR Death* OR
Dying)) OR "Aid
in dying" OR
"Mercy killing"
OR (Life NEAR/2
(Shorten* or
Termination)) OR
("End of life"
NEAR/2 (Decision*
OR Practice*)) OR
"Lethal drug*"
OR (Sedation
NEAR/2 (Deep OR
Continuous OR
Terminal)))
TI,SU(Euthanasia*
OR (Assisted
NEAR/2 (Suicide*
OR Death* OR
Dying)) OR "Aid
in dying" OR
"Mercy killing"
OR (Life NEAR/2
(Shorten* or
Termination))
OR ("End of life"
NEAR/2 (Decision*
OR Practice*)) OR
"Lethal drug*"
OR (Sedation
NEAR/2 (Deep OR
Continuous OR
Terminal)))
TI,AB,SU(Euthanasia*
OR (Assisted NEAR/2
(Suicide* OR Death*
OR Dying)) OR "Aid
in dying" OR "Mercy
killing" OR (Life
NEAR/2 (Shorten*
or Termination)) OR
("End of life" NEAR/2
(Decision* OR
Practice*)) OR
"Lethal drug*" OR
(Sedation NEAR/2
(Deep OR
Continuous OR
Terminal)))
TI,AB,SU(Euthanasia*
OR (Assisted NEAR/2
(Suicide* OR Death*
OR Dying)) OR "Aid
in dying" OR "Mercy
killing" OR (Life
NEAR/2 (Shorten* or
Termination)) OR
("End of life" NEAR/2
(Decision* OR
Practice*)) OR
"Lethal drug*" OR
(Sedation NEAR/2
(Deep OR
Continuous OR
Terminal)))
Systematic
review
Meta-analysis[PT] or
((Review[PT] or
Review[TI]) AND
(PubMed[TIAB] or
Medline[TIAB] or
Embase[TIAB] or
CINAHL[TIAB] or
PsycInfo[TIAB])) or
Cochrane Database
Syst Rev[TA] or Meta-
Analysis[TI] or Meta
analys*[TI] or
Systematic[TI]
Meta analysis/
OR Systematic
review/or ((Review/or
Review.ti) AND
(PubMed or Medline
or Embase or CINAHL
or PsycInfo).ab) or
Cochrane.jw or
(Meta-Analysis or
Metaanalys* or
Systematic).ti
(Meta analysis or
Systematic
review).id,md or
((Literature review/
or Literature
Review.id,md or
Review.ti) AND
(PubMed or Medline
or Embase or
CINAHL).ab) or
Cochrane.jw or
(Meta-Analysis or
Metaanalys* or
Systematic).ti
TS = (PubMed
or Medline or
Embase or CINAHL
or PsycInfo) AND
DOCUMENT TYPES:
(Review) OR TI =
("Meta Analysis" OR
Systematic OR
Metaanalys*)
MH "Meta-Analysis"
or MH "Systematic
review" OR PT
Systematic review
or ((PT Review or
TI Review) AND
AB (PubMed or
Medline or Embase
or CINAHL or
PsycInfo)) or JT
Cochrane or TI
(Meta-Analysis or
Metaanalys* or
Systematic)
Empirical
studies
Comparative study[PT]
or Observational
Study[PT] OR Cohort
studies[MH] OR Cross-
Sectional Studies[MH]
OR Cross Cultural
Comparison[MH] or
Anthropology,
Comparative study/or
Observational study/
or Cohort analysis/or
Longitudinal study/or
Prospective study/OR
Retrospective study/
or Cross-sectional
study/or Cultural
(Empirical study
or Focus group
or Followup study
or Interview or
Longitudinal study
or Prospective study
or Qualitative study
or Quantitative
TS = ("Before and
after" OR Cohort OR
"Cross sectional" OR
"Cultural
anthropolog*"
OR Empirical OR
Ethnograph* OR
"Focus group?" OR
MH "Comparative
studies" OR MH
"Cross Sectional
Studies" OR MH
"Prospective studies
+ " OR MH
"Retrospective
design" OR MH
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Table 2 The search terms for each academic database (Continued)
Cultural[MH:NOEXP]
OR Empirical research[MH]
OR "Interviews as Topic
"[MH] OR Questionnaires
[MH] OR "Physician's
Practice Patterns"[MH]
OR "Statistics and
numerical data"[SH]
OR Trends[SH] OR
"Before and after"[TI]
OR Cohort[TI] OR
Comparison[TI] OR
Comparative[TI] OR
Cross sectional[TI] OR
Cultural anthropolog*[TI]
OR Descriptive[TI] OR
Empirical[TI] OR
Ethnograph*[TI] OR
Focus group*[TI] OR
Follow back[TI] OR
Follow up[TI] OR
Interview*[TI] OR
Longitudinal[TI] OR
Observational[TI] OR
Population based[TI]
OR Qualitative[TI] OR
Questionnaire*[TI] OR
Prospective[TI] OR
Retrospective[TI] OR
Survey[TI] OR Surveys
[TI] OR Trend[TI] OR
Trends[TI]
anthropology/or
Ethnography/or
Empirical Research/
or Exp Interview/or
Qualitative research/
or Exp Questionnaire/
or Clinical practice/or
Trend study/or
("Before and after"
OR Cohort OR
Comparison OR
Comparative OR
Cross sectional OR
Cultural anthropolog*
OR Descriptive OR
Empirical OR
Ethnograph* OR
Focus group? OR
Follow back OR
Follow up OR
Interview? OR
Longitudinal OR
Observational OR
Population based OR
Qualitative OR
Questionnaire? OR
Prospective OR
Retrospective OR
Survey? OR Trend?).ti
study or
Retrospective
study).md or Cross
Cultural Differences/
or "Culture
(Anthropological)"/
or Ethnography/or
Questionnaires/or
Exp Surveys/or
Clinical practice/or
Trends/
"Follow back" OR
"Follow up" OR
Interview? OR
Longitudinal OR
Observational OR
"Population based"
OR Qualitative OR
Questionnaire? OR
Prospective OR
Retrospective OR
Survey? OR Trend?)
or TI = (Comparison
OR Comparative OR
Descriptive)
"Questionnaires + "
OR MH "Empirical
Research" OR MH
"Qualitative Studies
+ " OR MH "Focus
groups" or MH
Interviews +OR MH
"Quantitative Studies"
OR MH "Quasi-
Experimental Studies
+ " OR TI ("Before
and after" OR Cohort
OR Comparison OR
Comparative OR
Cross sectional OR
Cultural
anthropolog* OR
Descriptive OR
Empirical OR
Ethnograph* OR
Focus group? OR
Follow back OR
Follow up OR
Interview? OR
Longitudinal OR
Observational OR
Population based OR
Qualitative OR
Questionnaire? OR
Prospective OR
Retrospective OR
Survey? OR Trend?)
*truncation symbol to search for all terms that have the same root words
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Appendix 2
Table 3 Variations in study methods for 39 jurisdiction-wide surveys and 22 included in analysis of practice variation
Surveys [1] Included
for practice
variation
analysis
Reasons for
exclusion [2]
Article information [3] Characteristics of professionals surveyed Characteristics of patients
Title Year of
publication
Authors
Netherlands
1995a
Yes Euthanasia and other end-of-life
decisions in the Netherlands in
1990,1995, and 2001
2003 Onwuteaka-Philipsen, Bregie
D.van der Heide, AgnesKoper,
DirkKeij-Deerenberg, Ingeborg
Rietjens, Judith A.Rurup, Mette
L.Vrakking, Astrid M.Georges,
Jean JacquesMuller, Martien
T.van der Wal, Gerritvan der
Maas, Paul J.
1) Specialities; 2) to be actively practising
medicine at the time of interview and
had to have done so for the previous
2 years in the same specialty and place
Exclusion criteria: the cause of
death precluded any kind of end-
of-life decision (e.g., a car accident
resulting in instant death)
Netherlands
1990a
Yes Euthanasia and other medical
decisions concerning the end
of life
1991 van der Maas, P. J.Vandelden,
J. J. M.Pijnenborg, L.Looman,
C. W. N.
1) A stratified random sample of 405
physicians was interviewed, including
152 general practitioners, 50 nursing-
home physicians, and 203 specialists
(cardiologists, surgeons, and specialists
in internal medicine, chest disease, and
neurology). (Method, section I Interviews
with physicians); 2) 6642 Dutch doctors
who had signed a death certificate for
which medical end-of-life decision were
possible (excluding sudden deaths, such
accidents.) 5197 responded and returned
the questionnaires
For all inhabitants of the
Netherlands the cause of death is
reported to the Central Bureau of
Statistics (CBS). The name of the
patient is not mentioned on the
cause-of-death form but that of the
reporting physician is. The medical
officer in charge of the cause-of-
death statistics drew a stratified
sample of 7000 deaths from Aug 1
to Dec 1, 1990.
Netherlands
2001a
Yes Euthanasia and other end-of-life
decisions in the Netherlands in
1990,1995, and 2001
2003 Onwuteaka-Philipsen, Bregie
D.van der Heide, AgnesKoper,
DirkKeij-Deerenberg, Ingeborg
Rietjens, Judith A.Rurup, Mette
L.Vrakking, Astrid M.Georges,
Jean JacquesMuller, Martien
T.van der Wal, Gerritvan der
Maas, Paul J.
1) Specialities; 2) to be actively practising
medicine at the time of interview and
had to have done so for the previous
2 years in the same specialty and place.
Exclusion criteria: the cause of death
precluded any kind of end-of-life
decision (e.g., a car accident resulting
in instant death)
Netherlands
1990b
Yes Euthanasia and other medical
decisions concerning the end
of life
1991 van der Maas, P. J.Vandelden,
J. J. M.Pijnenborg, L.Looman,
C. W. N.
1) A stratified random sample of 405
physicians was interviewed, including
152 general practitioners, 50 nursing-
home physicians, and 203 specialists
(cardiologists, surgeons, and specialists
in internal medicine, chest disease, and
neurology). (Method, section I Interviews
with physicians); 2) 6642 Dutch doctors
who had signed a death certificate for
which medical end-of-life decision were
possible (excluding sudden deaths, such
accidents.) 5197 responded and returned
the questionnaires (Method; Section II
Death certificates)
For all inhabitants of the Netherlands
the cause of death is reported to the
Central Bureau of Statistics (CBS). The
name of the patient is not mentioned
on the cause-of-death form but that
of the reporting physician is. The
medical officer in charge of the cause-
of-death statistics drew a stratified
sample of 7000 deaths from Aug 1
to Dec 1, 1990.
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Table 3 Variations in study methods for 39 jurisdiction-wide surveys and 22 included in analysis of practice variation (Continued)
Netherlands
2010a
Yes Trends in end-of-life practices
before and after the enactment
of the euthanasia law in the
Netherlands from 1990 to 2010:
a repeated cross-sectional survey
2012 Onwuteaka-Philipsen, Bregje D.
Brinkman-Stoppelenburg,
AriannePenning, Corinede
Jong-Krul, Gwen J.van Delden,
Johannes J.van der Heide, Agnes
All attending physicians of the sampled
cases in strata two to five (See question
6) received a questionnaire.
1) All deaths that occurred in that
period were assigned to one of five
strata. When the cause of death
clearly precluded end-of-life decision-
making), cases were assigned to
stratum one. These cases were
retained in the sample, but no
questionnaires were sent out to the
physician. Cases were assigned to
one of the other strata looking at
the likelihood that an end-of-life
decision had preceded death: when
this decision was unlikely cause of
death was allocated to stratum two,
when this decision was possible to
stratum three, and when this decision
was more probable (e.g., cancer) to
stratum four. Cases were assigned to
stratum five when the physician had
noted on the death certificate that
they had actively ended the life of
the patient.
Belgium
(Flanders)
2001/2002a
Yes End-of-life medical decisions in
six European countries: Belgium,
Denmark, Italy, the Netherlands,
Sweden and Switzerland. [Dutch]
medische besluiten rond het
levenseinde in 6 europese
landen: belgie, denemarken,
italie, nederland, zweden en
zwitserland
2003 Van Der Heide, A.Deliens, L.Faisst,
K.Nilstun, T.Norup, M.Paci, E.Van
Der Wal, G.Van Der Maas, P. J.
Danish, Italian, and Dutch samples
included a stratum in which end-of-life
decisions were precluded on the basis
of information on the death certificate,
for which no questionnaires were sent
out. For all other sampled cases, the
attending doctors were asked if death
had arisen suddenly and unexpectedly.
Random samples of death certificates
of people aged 1 year or older from
death registries to which all deaths are
reported. The sampling period varied
between 3 and 6 months, but all
deaths that we included arose
between June 2001, and February
2002.
Netherlands
2001b
Yes Euthanasia and other end-of-
life decisions in the Netherlands
in 1990, 1995, and 2001
2003 Onwuteaka-Philipsen, Bregie
D.van der Heide, AgnesKoper,
DirkKeij-Deerenberg, Ingeborg
Rietjens, Judith A.Rurup, Mette
L.Vrakking, Astrid M.Georges,
Jean JacquesMuller, Martien
T.van der Wal, Gerritvan der
Maas, Paul J.
1) Specialities; 2) to be actively practising
medicine at the time of interview and
had to have done so for the previous
2 years in the same specialty and place
Exclusion criteria: the cause of death
precluded any kind of end-of-life
decision (e.g., a car accident resulting
in instant death)
Denmark
2001/2002a
Yes End-of-life medical decisions in
six European countries: Belgium,
Denmark, Italy, the Netherlands,
Sweden and Switzerland. [Dutch]
medische besluiten rond het
levenseinde in 6 europese landen:
belgie, denemarken, italie,
nederland, zweden en zwitserland
2003 Van Der Heide, A.Deliens, L.
Faisst, K.Nilstun, T.Norup, M.
Paci, E.Van Der Wal, G.Van Der
Maas, P. J.
Danish, Italian, and Dutch samples
included a stratum in which end-of-life
decisions were precluded on the basis
of information on the death certificate,
for which no questionnaires were sent
out. For all other sampled cases, the
attending doctors were asked if death
had arisen suddenly and unexpectedly.
Random samples of death certificates
of people aged 1 year or older from
death registries to which all deaths
are reported. The sampling period
varied between 3 and 6 months,
but all deaths that we included
arose between June 2001, and
February 2002.
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Table 3 Variations in study methods for 39 jurisdiction-wide surveys and 22 included in analysis of practice variation (Continued)
Netherlands
1994–1998
(ALS patients)
No Specific
population of
patients
Euthanasia and physician-assisted
suicide in Dutch patients with
amyotrophic lateral sclerosis.
[Dutch] euthanasie en hulp bij
zelfdoding bij patienten met
amyotrofische laterale sclerose
in nederland
2004 Veldink, J. H.Wokke, J. H. J.Van
Der Wal, G.De Jong, J. M. B. V.
Van Den Berg, L. H.
The family physicians of 279 Dutch
patients who fulfilled the criteria for
possible, probable or definite ALS, who
were known in the Utrecht University
Medical Centre or the Academic Medical
Centre in Amsterdam, the Netherlands,
and who had died in the period 1994–
1998 were asked to fill out a validated
questionnaire about the various medical
end-of-life decisions that had been taken
and their possible clinical, care-related
and social determinants.
NA
Australia
1996b
Yes End-of-life decisions in Australian
medical practice
1997 Kuhse, H.Singer, P.Baume, P.
Clark, M.Rickard, M.
1. 3000 doctors taken at random from a
list of 27000 Australian doctors extracted
from the Australian Medical Masterfile
Database (Australasian Medical
Publishing Company, Sydney), one of 27
medical disciplines where there would
be the possibility of making a medical
end-of-life decision; 2- the 27 medical
disciplines (also extracted from the
Australian Medical Masterfile Database)
as comparable as possible with the
broader categories of doctors
(cardiology, surgery, internal medicine,
respiratory medicine [pulmonology],
neurology, general practitioners and
nursing home physicians) who were
attendant to 87 % of hospital deaths
and nearly all deaths outside hospitals
in the Netherlands; 3- The initial
questions on the questionnaire
narrowed the field of respondents to
include the 1361 doctors who had
attended a death within the last
12 months.
NA
Sweden
2001/2002a
Yes End-of-life medical decisions in
six European countries: Belgium,
Denmark, Italy, the Netherlands,
Sweden and Switzerland. [Dutch]
medische besluiten rond het
levenseinde in 6 europese landen:
belgie, denemarken, italie,
nederland, zweden en zwitserland
2003 Van Der Heide, A.Deliens, L.
Faisst, K.Nilstun, T.Norup, M.Paci,
E.Van Der Wal, G.Van Der Maas,
P. J.
Danish, Italian, and Dutch samples
included a stratum in which end-
of-life decisions were precluded
on the basis of information on the
death certificate, for which no
questionnaires were sent out. For
all other sampled cases, the
attending doctors were asked if
death had arisen suddenly and
unexpectedly.
Random samples of death certificates
of people aged 1 year or older from
death registries to which all deaths
are reported. The sampling period
varied between 3 and 6 months, but
all deaths that we included arose
between June 2001, and February
2002.
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Table 3 Variations in study methods for 39 jurisdiction-wide surveys and 22 included in analysis of practice variation (Continued)
Netherlands
2001/2002a
Yes End-of-life medical decisions in
six European countries: Belgium,
Denmark, Italy, the Netherlands,
Sweden and Switzerland.
[Dutch] medische besluiten
rond het levenseinde in 6
europese landen: belgie,
denemarken, italie, nederland,
zweden en zwitserland
2003 Van Der Heide, A.Deliens, L.
Faisst, K.Nilstun, T.Norup, M.Paci,
E.Van Der Wal, G.Van Der Maas,
P. J.
Danish, Italian, and Dutch samples
included a stratum in which end-of-
life decisions were precluded on
the basis of information on the
death certificate, for which no
questionnaires were sent out. For
all other sampled cases, the attending
doctors were asked if death had arisen
suddenly and unexpectedly.
Random samples of death certificates
of people aged 1 year or older from
death registries to which all deaths are
reported. The sampling period varied
between 3 and 6 months, but all
deaths that we included arose
between June 2001, and February
2002.
Switzerland
(German-
speaking)
2001/2002a
Yes End-of-life medical decisions
in six European countries:
Belgium, Denmark, Italy, the
Netherlands, Sweden and
Switzerland. [Dutch] medische
besluiten rond het levenseinde
in 6 europese landen: belgie,
denemarken, italie, nederland,
zweden en zwitserland
2003 Van Der Heide, A.Deliens, L.Faisst,
K.Nilstun, T.Norup, M.Paci, E.Van
Der Wal, G.Van Der Maas, P. J.
Danish, Italian, and Dutch samples
included a stratum in which end-
of-life decisions were precluded
on the basis of information on the
death certificate, for which no
questionnaires were sent out. For all
other sampled cases, the attending
doctors were asked if death had
arisen suddenly and unexpectedly.
Random samples of death certificates
of people aged 1 year or older from
death registries to which all deaths
are reported. The sampling period
varied between 3 and 6 months, but
all deaths that we included arose
between June 2001, and February
2002.
UK 2007/2008b Yes Hastening death in end-of-life
care: a survey of doctors
2009 Seale, Clive 1) Binley’s database (http://www.binleys.com/)
of UK medical practitioners was used
to send questionnaires to 8857 working
UK medical practitioners, comprising
separate random samples of 2829 GPs,
443 neurologists, 836 specialists in care
of the elderly, 462 specialists in palliative
medicine and 4287 in other hospital
specialties in 2007 to 2008; 2) Excluding
specialties such as public health where
doctors do not normally treat people
who die; 3) Neurologists, palliative
medicine and care of the elderly
specialists were over sampled in relation
to their proportions in the medical
population to enable exploration of the
circumstances of elderly people, people
receiving specialist palliative care, and
those with multiple sclerosis (MS) and
motor neurone disease (MND).
NA
Italy
2001/2002a
Yes End-of-life medical decisions
in six European countries:
Belgium, Denmark, Italy, the
Netherlands, Sweden and
Switzerland. [Dutch] medische
besluiten rond het levenseinde
in 6 europese landen: belgie,
denemarken, italie, nederland,
zweden en zwitserland
2003 Van Der Heide, A.Deliens, L.Faisst,
K.Nilstun, T.Norup, M.Paci, E.Van
Der Wal, G.Van Der Maas, P. J.
Danish, Italian, and Dutch samples
included a stratum in which end-
of-life decisions were precluded
on the basis of information on the
death certificate, for which no
questionnaires were sent out. For all
other sampled cases, the attending
doctors were asked if death had
arisen suddenly and unexpectedly.
Random samples of death certificates of
people aged 1 year or older from death
registries to which all deaths are
reported. The sampling period varied
between 3 and 6 months, but all
deaths that we included arose between
June 2001, and February 2002.
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Table 3 Variations in study methods for 39 jurisdiction-wide surveys and 22 included in analysis of practice variation (Continued)
Belgium
(Flanders)
1998a
Yes The incidence and characteristics
of end-of-life decisions by GPs
in Belgium
2004 Bilsen, JohanStichele, Robert
VanderMortier, Freddy
Bernheim, JanDeliens, Luc
Identified the speciality of the
attesting physicians (GP or specialist)
for each of the 3999 sampled death
certificates and selected only the
cases in the data set for which a GP
returned the questionnaire
"A 20 % random sample was taken
from all death certificates signed
between January 1 and April 30, 1998."
Belgium
2005/2006a
Yes Euthanasia and other end of life
decisions and care provided in
final three months of life:
nationwide retrospective study
in Belgium
2009 Van Den Block, L.Deschepper,
R.Bilsen, J.Bossuyt, N.Van
Casteren, V.Deliens, L.
Inclusion criteria: registered the death
of a patient between 1 January 2005
and 31 December 2006 in Belgium
Inclusion Criteria: 1) Died between 1
January 2005 and 31 December 2006
in Belgium; 2) Be over the age of
one year; 3) Non-sudden death
France 2009a Yes End-of-life medical decisions in
France: a death certificate follow-
up survey 5 years after the 2005
act of parliament on patients'
rights and end of life
2012 Pennec, S.Monnier, A.
Pontone, S.Aubry, R.
Inclusion criteria: Having completed
a death certificate in December 2009
1) Aged 18 and over; 2) died in
France in December 2009
Netherlands
1990 (Prospective)
Yes Euthanasia and other medical
decisions concerning the end
of life
1991 van der Maas, P. J.Vandelden,
J. J. M.Pijnenborg, L.Looman,
C. W. N.
1) A stratified random sample of
405 physicians was interviewed,
including 152 general practitioners,
50 nursing-home physicians, and
203 specialists (cardiologists,
surgeons, and specialists in internal
medicine, chest disease, and
neurology). (Method, section I
Interviews with physicians); 2) 6642
Dutch doctors who had signed a
death certificate for which medical
end-of-life decision were possible
(excluding sudden deaths, such
accidents.) 5197 responded and
returned the questionnaires
For all inhabitants of the Netherlands
the cause of death is reported to the
Central Bureau of Statistics (CBS). The
name of the patient is not mentioned
on the cause-of-death form but that
of the reporting physician is. The
medical officer in charge of the
cause-of-death statistics drew a
stratified sample of 7000 deaths from
Aug 1 to Dec 1, 1990.
Netherlands
1995b
Yes Euthanasia and other end-of-life
decisions in the Netherlands in
1990,1995, and 2001
2003 Onwuteaka-Philipsen, Bregie
D.van der Heide, AgnesKoper,
DirkKeij-Deerenberg, Ingeborg
Rietjens, Judith A.Rurup, Mette
L.Vrakking, Astrid M.Georges,
Jean JacquesMuller, Martien
T.van der Wal, Gerritvan der
Maas, Paul J.
1) Specialities; 2) to be actively
practising medicine at the time
of interview and had to have
done so for the previous 2 years
in the same specialty and place
Exclusion criteria : the cause of
death precluded any kind of end-
of-life decision (e.g., a car accident
resulting in instant death)
Belgium
(Flanders)
1999/2000c
No Specific
population of
patients
The first five years of euthanasia
legislation in Belgium and the
Netherlands: Description and
comparison of cases
2012 Rurup, Mette L.Smets, Tinne
Cohen, JoachimBilsen, Johan
Onwuteaka-Philipsen, Bregje
D.Deliens, Luc
The anonymized databases of the
reported cases of euthanasia in
Belgium and the Netherlands were
made available by the review
committees. We selected all cases
reported between 22 September
2002 (date of first report in Belgium)
and the end of 2007 in both
databases
The anonymized databases of the
reported cases of euthanasia in
Belgium and the Netherlands were
made available by the review
committees. We selected all cases
reported between 22 September
2002 (date of first report in Belgium)
and the end of 2007 in both
databases
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Table 3 Variations in study methods for 39 jurisdiction-wide surveys and 22 included in analysis of practice variation (Continued)
Netherlands
2005a
Yes End-of-Life Practices in the
Netherlands under the
Euthanasia Act
2007 van der Heide, A., B. D. Onwuteaka-
Philipsen, M. L. Rurup, H. M.
Buiting, J. J. van Delden, J. E.
Hanssen-de Wolf, A. G. Janssen,
H. Pasman, J. A. Rietjens, C. J.
Prins, I. M. Deerenberg, J. K.
Gevers, P. J. van der Maas and
G. van der Wal
1) To be licensed physicians
practicing in Oregon from the
Oregon State Board of Medical
Examiners (BME) in November
1994; 2) We defined “attending
physicians” as all physicians in
Oregon licensed in the following
specialties: internal medicine,
family practice, general practice,
neurology, gynaecology,
therapeutic radiology, and surgery
NA
Netherlands
2001c
No Specific
population of
patients
[No conspicuous changes in
the practice of medical end-of-
life decision-making for neonates
and infants in the Netherlands in
2001 as compared to 1995]
2005 Vrakking, A. M.van der Heide,
A.Onwuteaka-Philipsen, B. D.
Keij-Deerenberg, I. M.van der
Maas, P. J.van der Wal, G.
The questionnaires which were
sent to the physicians who
reported the deaths, included
structured questions about
whether or not death had been
preceded by end-of-life decisions,
i.e. decisions to withhold or
withdraw potentially life-prolonging
treatment or to administer
(potentially) life-shortening drugs,
and questions about the decision-
making process.
In both years, all deaths of children
under the age of one year that took
place in August-November (1995:
n = 338; 2001: n = 347) were studied
Netherlands
2005/2006
(HGG patients)
No Specific
population of
patients
Decision-making in the end-of-
life phase of high-grade glioma
patients
2012 Sizoo, E. M.Pasman, H. R.Buttolo,
J.Heimans, J. J.Klein, M.Deliens,
L.Reijneveld, J. C.Taphoorn, M. J.
"The physicians involved in end-of-
life care of deceased patients of the
cohort were approached for
participation in the study. (…) If
more than one physician was
involved in end of life care for a
specific patient (for example due to
a transition in health care setting
close before death), all physicians
were approached for participation
in the study"
"adult HGG patients diagnosed in
2005 and 2006 in three tertiary
referral centres for brain tumour
patients (VU University Medical
Centre and Academic Medical
Centre Amsterdam Amsterdam,
Medical Centre Haaglanden The
Hague, The Netherlands)"
Netherlands
1995c
No Specific
population of
patients
[No conspicuous changes in
the practice of medical end-of-
life decision-making for neonates
and infants in the Netherlands in
2001 as compared to 1995]
2005 Vrakking, A. M.van der Heide,
A.Onwuteaka-Philipsen, B. D.
Keij-Deerenberg, I. M.van der
Maas, P. J.van der Wal, G.
The questionnaires which were sent
to the physicians who reported the
deaths, included structured questions
about whether or not death had
been preceded by end-of-life
decisions, i.e. decisions to withhold
or withdraw potentially life-prolonging
treatment or to administer
(potentially) life-shortening drugs,
and questions about the decision-
making process.
In both years, all deaths of children
under the age of one year that took
place in August-November (1995:
n = 338; 2001: n = 347) were studied
Belgium
(Hasselt,
Flanders)
1996a
Yes Attitudes, socio-demographic
characteristics, and actual end-
of-life decisions of physicians
in Flanders, Belgium
2003 Mortier, F.Bilsen, J.Vander Stichele,
R. H.Bernheim, J.Deliens, L.
"All physicians who signed a death
certificate" in 1996 in the city of
Hasselt (Flanders)
"All official death certificates of the
970 deaths in Hasselt in 1996 were
retrieved for the study."
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Table 3 Variations in study methods for 39 jurisdiction-wide surveys and 22 included in analysis of practice variation (Continued)
Belgium
(Flanders)
2007a
Yes Trends in medical end-of-life
decision making in Flanders,
Belgium 1998-2001-2007
2011 Chambaere, K.Bilsen, J.Cohen,
J.Onwuteaka-Philipsen, B. D.
Mortier, F.Deliens, L.
Every certifying physician was
sent a 5-page questionnaire for a
maximum of 5 cases, with at most
3 reminders in case of nonresponse.
We performed a death certificate
survey in Flanders, the Flemish-
speaking part of Belgium, which has
about 6 million inhabitants and
approximately 55,000 deaths per
year. This study was similar to those
performed in 1998 and 2001. A
stratified random sample of deaths
was drawn by the central
administration authority for death
certificates, the Flemish Agency for
Care and Health. All deaths between
1 June 2007 and 30 November 2007
of Belgian residents aged 1 year or
older were first assigned to 1 of 4
strata, based on the underlying cause
of death as indicated on the death
certificate and the estimated
corresponding likelihood of an
end-of-life practice. Sampling fractions
for each stratum increased with this
likelihood.
Netherlands
2005/2006
(Neonates/infants
(Aug to Nov))
No Specific
population of
patients
Analgesics, sedatives and
neuromuscular blockers as part
of end-of-life decisions in Dutch
NICUs
2009 Verhagen, A. A.Dorscheidt, J. H.
Engels, B.Hubben, J. H.Sauer, P. J.
Caring of a infants for newborns
in group II (Patients and methods -
Interviews, p.F435); Group II :
stabilised newborns with a poor
prognosis
"infants who died before the age of
2 months between October 2005
and September 2006 in the NICUs"
Sweden 1998b No Specific
population
of physicians
Palliative care, assisted suicide
and euthanasia: Nationwide
questionnaire to Swedish
physicians
2000 Valverius, E.Nilstun, T.Nilsson, B. Inclusion criteria: Swedish
Pharmaceutical Statistics OR
working in palliative care units in
Sweden OR members of the
Swedish Association for the Study
of Pain
Inclusion criteria: deceased during 1997
UK 2004b Yes National survey of end-of-life
decisions made by UK medical
practitioners
2006 Seale, C. 1) A random sample of 1000 general
practitioners (GPs) and 1000 hospital
specialists listed on Binley’s database
(www.binleys.com) of all working UK
medical practitioners (updated in
September 2004) were sent
questionnaires, with two follow-up
reminders, between October and
December 2004; 2) specialties where
doctors could not be expected to
have attended a death in the previous
year (e.g., public health) were excluded
NA
Netherlands
2005/2006
(Neonates/
infants (group I))
No Specific
population of
patients
Analgesics, sedatives and
neuromuscular blockers as
part of end-of-life decisions
in Dutch NICUs
2009 Verhagen, A. A.Dorscheidt, J.
H.Engels, B.Hubben, J. H.Sauer,
P. J.
Caring of a infants for newborns in
group II (Patients and methods -
Interviews, p.F435); Group II :
stabilised newborns with a poor
prognosis
"infants who died before the age of
2 months between October 2005
and September 2006 in the NICUs"
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Table 3 Variations in study methods for 39 jurisdiction-wide surveys and 22 included in analysis of practice variation (Continued)
Belgium
(Flanders)
2007 (Death
certificates
(cancer patients))
Yes Trends in End-of-Life Decision
Making in Patients With and
Without Cancer
2013 Pardon, KoenChambaere,
KennethPasman, H. Roeline
W.Deschepper, ReginaldRietjens,
JudithDeliens, Luc
Physicians who had attested to the
sampled death certificates were sent
a 5-page paper-and-pencil
questionnaire by the Flemish Agency
about the medical decisions made at
the patient’s end of life, the decision-
making process, and the care provided.
We conducted a nationwide death
certificate study in 2007 in Flanders,
analogous to our death certificate
study of 1998. The Flemish Agency
for Care and Health selected a
random stratified sample of all death
certificates of persons ages 1 year or
older from June to November 2007.
Belgium
(Flanders)
2007 (Death
certificates
(non-cancer
patients))
Yes Trends in End-of-Life Decision
Making in Patients With and
Without Cancer
2013 Pardon, KoenChambaere,
KennethPasman, H. Roeline W.
Deschepper, ReginaldRietjens,
JudithDeliens, Luc
Physicians who had attested to the
sampled death certificates were sent
a 5-page paper-and-pencil
questionnaire by the Flemish Agency
about the medical decisions made at
the patient’s end of life, the decision-
making process, and the care provided.
We conducted a nationwide death
certificate study in 2007 in Flanders,
analogous to our death certificate
study of 1998. The Flemish Agency
for Care and Health selected a
random stratified sample of all death
certificates of persons ages 1 year or
older from June to November 2007.
Netherlands
2001 (Children
(1 to 17y) (Aug
to Dec))
No Specific
population of
patients
Medical end-of-life decisions for
children in the Netherlands
2005 Vrakking, A. M.van der Heide,
A.Arts, W. F.Pieters, R.van der
Voort, E.Rietjens, J. A.Onwuteaka-
Philipsen, B. D.van der Maas, P.
J.van der Wal, G.
Inclusion criteria: have reported a
death of a child between August 1
and December 1, 2001.
STUDY 1:Inclusion criteria: have died
between August 1 and December 1,
2001 in the Netherlands, aged
between 1–17 years
Netherlands
2005/2006
(Neonates/
infants (group II))
No Specific
population of
patients
Analgesics, sedatives and
neuromuscular blockers as
part of end-of-life decisions
in Dutch NICUs
2009 Verhagen, A. A.Dorscheidt, J.
H.Engels, B.Hubben, J. H.Sauer,
P. J.
Caring of a infants for newborns in
group II (Patients and methods -
Interviews, p.F435); Group II : stabilised
newborns with a poor prognosis
"infants who died before the age of
2 months between October 2005
and September 2006 in the NICUs"
Netherlands
1996–1998
(Dementia in
nursing homes)
No Specific
population of
patients
End-of-Life Decision Making in
Nursing Home Residents with
Dementia and Pneumonia:
Dutch Physicians' Intentions
Regarding Hastening Death
2005 van der Steen, Jenny T.van der
Wal, GerritMehr, David R.Ooms,
Marcel E.Ribbe, Miel W.
Nursing home physicians, who are
employed by the nursing home in
the Netherlands, completed
questionnaires regarding their
decisions and treatments at the time
of deciding to withhold antibiotics.
We identified eligible subjects from
a nationwide Dutch study of 706
nursing home residents with
dementia who were diagnosed with
pneumonia. For the present analyses,
we first selected the 165 (23 %)
patients who physicians decided not
to treat with antibiotics. As shown in
Figure 1, we excluded 22 patients,
including 12 who survived for
3 months and 8 who died of
another cause or a second episode
of pneumonia.
Belgium
(Flanders)
2007/2008
(NSCLC patients)
No Specific
population of
patients
Expressed wishes and incidence
of euthanasia in advanced lung
cancer patients
2012 Pardon, K.Deschepper, R.Vander
Stichele, R.Bernheim, J. L.Mortier,
F.Schallier, D.Germonpre, P.
Galdermans, D.Van Kerckhoven,
W.Deliens, L.Eolic Consortium
We asked the pulmonologist or
oncologist and the general
practitioner (GP) of the patient
to fill in an after-death questionnaire
for those patients who died within
18 months of inclusion in the study.
Patients conformed to the following
inclusion criteria: a recent initial
diagnosis of non-small cell lung
cancer (NSCLC) stage IIIb or IV, 18 yrs.
or older, Dutch speaking and physically
and psychologically able to participate
in the study. The patients were r
ecruited consecutively during one year
by pulmonologists and oncologists in
13 hospitals in Flanders.
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Table 3 Variations in study methods for 39 jurisdiction-wide surveys and 22 included in analysis of practice variation (Continued)
Sweden 1998
(Palliative care
physicians)
No Specific
population
of physicians
Palliative care, assisted suicide
and euthanasia: Nationwide
questionnaire to Swedish
physicians
2000 Valverius, E.Nilstun, T.Nilsson, B. Inclusion criteria: Swedish
Pharmaceutical Statistics OR
working in palliative care units in
Sweden OR members of the Swedish
Association for the Study of Pain
Inclusion criteria: deceased during 1997
Sweden 1998
(Association for
the Study of
Pain Physicians)
No Specific
population of
physicians
Palliative care, assisted suicide
and euthanasia: Nationwide
questionnaire to Swedish
physicians
2000 Valverius, E.Nilstun, T.Nilsson, B. Inclusion criteria: Swedish
Pharmaceutical Statistics OR
working in palliative care units in
Sweden OR members of the
Swedish Association for the Study
of Pain
Inclusion criteria: deceased
during 1997
EUROPE 2005
(RICU patients)
No Specific
population of
patients
End-of-life decision-making in
respiratory intermediate care
units: A European survey
2007 Nava, S.Sturani, C.Hartl, S.Magni,
G.Ciontu, M.Corrado, A.Simonds, A.
Once approved by the ERS office,
a formal letter was sent by e-mail
to all of the participants in the
census on the epidemiology of
RICUs in Europe, performed in
2002, and all members of the
ERS Respiratory Intensive Care
Assembly to invite them to
participate in the present study.
The aim of this task force, conducted
between May 1, 2005 and October
31, 2005, was to collect data
regarding end-of-life decisions in
RICUs and high dependency units
(HDUs) within Europe by means of a
prospective questionnaire.
New Zealand
2000b
Yes Specific
population
of physicians
End of life decision-making
by New Zealand general
practitioners: A national survey
1196 Mitchell, K.Owens, R. G. 1) The questionnaire was
administered to GPs in New
Zealand (in August and September,
2000). It asked for details on the
last death in the previous 12 months
for which the physician was the
attendant doctor, and whether that
physician had access to a
multidisciplinary palliative care team;
2) There are approximately 3000
practising GPs in New Zealand and a
questionnaire was sent to 2602 on a
commercial mailing list.
NA
Note: [1] the end-of-life surveys were identified by the jurisdictions of investigation, year of study and methods to identify physicians; a = death certificate studies, b = physician survey, c = neonate or infant study; [2]
the term “exclusion” meant the surveys excluded from statistical analyses with other surveys because of the focus on specific populations or geographic regions; [3] the article listed in the table was the one that used
for data extraction; [4] the methods to identify physicians included death certificates, physicians (registries or associations), neonate/infants (patients or death certificates), or other specific patient groups; [5] the numbers
in the column might be the total numbers of deaths that the frequencies of end-of-life practices could be applied or total numbers of death studied; [6] differential response meant the response rates might differ across
sampling strata or subgroups; [7] selective reporting meant that not all results of a single study were reported in the article
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Table 3 Variations in study methods for 39 jurisdiction-wide surveys and 22 included in analysis of practice variation (Continued)
Surveys [1] Methods to identify
physicians [4]
Total number
of deaths
studied or
applicable [5]
Clear
selection
criteria
Data collection
method
Practice
measurement
method
Differential
response [6]
Selective
reporting
[7]
Response
rates
Netherlands
1995a
Death certificates 135675 Yes Self-administered
postal questionnaire
Annual incidence Uncertain Yes 77.0 %
Netherlands
1990a
Death certificates 128824 Yes NA Annual incidence No NA 76.0 %
Netherlands
2001a
Death certificates 140377 Yes Self-administered
postal questionnaire
Annual incidence Not reported Yes 74.00 %
Netherlands
1990b
Physicians 128824 Yes Interview Annual incidence Yes Yes 68.0 %
Netherlands
2010a
Death certificates 136056 Yes Self-administered
postal questionnaire
Annual incidence Yes Yes 74.0 %
Belgium
(Flanders)
2001/2002a
EURELD-death
certificates
55793 Yes NA Annual incidence No Yes 59.0 %
Netherlands
2001b
Physicians 140377 Yes Interview Annual incidence Yes Yes 85.0 %
Denmark
2001/2002a
EURELD-death
certificates
58722 Yes NA Annual incidence No Yes 62.0 %
Netherlands
1994–1998
(ALS patients)
ALS patients 279 Yes Self-administered
postal questionnaire
Annual incidence No Yes 84.0 %
Australia
1996b
Physicians 125771 Yes Self-administered
postal questionnaire
Annual incidence Yes Yes 64.0 %
Sweden
2001/2002a
EURELD-death
certificates
93755 Yes NA Annual incidence No Yes 61.0 %
Netherlands
2001/2002a
EURELD-death
certificates
140377 Yes NA Annual incidence No Yes 75.0 %
Switzerland
(German-
speaking)
2001/2002a
EURELD-death
certificates
44036 Yes NA Annual incidence No Yes 67.0 %
UK 2007/2008b Physicians 72071 Yes Self-administered
postal questionnaire
Annual incidence Yes Yes 42.1 %
Italy
2001/2002a
EURELD-death
certificates
22368 Yes NA Annual incidence No Yes 44.0 %
Belgium
(Flanders)
1998a
Death certificates 56354 Yes Self-administered
postal questionnaire
Annual incidence Not reported No 64.8 %
Belgium
2005/2006a
Death certificates 2690 Yes NA Annual incidence Yes Yes 64.3 %
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Table 3 Variations in study methods for 39 jurisdiction-wide surveys and 22 included in analysis of practice variation (Continued)
France 2009a Death certificates 47872 Yes Self-administered
postal questionnaire
Annual incidence Not reported Yes 40.0 %
Netherlands
1990 (Prospective)
Prospective 128786 Yes Self-administered
postal questionnaire
Annual incidence Not reported Yes 80.0 %
Netherlands
1995b
Physicians 135675 Yes Interview Annual incidence Not reported Yes 74.0 %
Belgium
(Flanders)
1999/2000c
Neonates/infants 292 Yes Self-administered
postal questionnaire
Annual incidence Not reported Yes 87.0 %
Netherlands
2005a
Death certificates 136402 Yes Self-administered
postal questionnaire
Annual incidence Not reported Yes 77.80 %
Netherlands
2001c
Neonates/infants 1088 Yes Self-administered
postal questionnaire
Annual incidence Not reported Yes 84.0 %
Netherlands
2005/2006
(HGG patients)
HGG patients 223 Yes Self-administered
questionnaire
Annual incidence No Yes 62.0 %
Netherlands
1995c
Neonates/infants 1041 Yes Self-administered
postal questionnaire
Annual incidence Not reported Yes 88.0 %
Belgium
(Hasselt,
Flanders)
1996a
Death certificates 970 Yes Self-administered
postal questionnaire
Annual incidence Yes Yes 55.0 %
Belgium
(Flanders)
2007a
Death certificates 54881 Yes Self-administered
postal questionnaire
Annual incidence Not reported Yes 58.4 %
Netherlands
2005/2006
(Neonates/infants
(Aug to Nov))
Neonates/infants
(Aug to Nov)
NA Yes Interview Annual incidence Not reported Yes 97.80 %
Sweden 1998b Physicians 952 Yes Self-administered
postal questionnaire
Annual incidence No Yes 78.0 %
UK 2004b Physicians 22558 Yes Self-administered
postal questionnaire
Annual incidence Not reported Yes 53.0 %
Netherlands
2005/2006
(Neonates/
infants (group I))
Neonates/infants
(group I)
359 Yes NA Annual incidence Yes Yes 98.00 %
Belgium
(Flanders)
2007 (Death
certificates
(cancer patients))
Death certificates
(cancer patients)
15257 Yes Self-administered
postal questionnaire
Annual incidence Yes Yes 58.4 %
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Table 3 Variations in study methods for 39 jurisdiction-wide surveys and 22 included in analysis of practice variation (Continued)
Belgium
(Flanders)
2007 (Death
certificates
(non-cancer
patients))
Death certificates
(non-cancer
patients)
39624 Yes Self-administered
questionnaire
Annual incidence Yes Yes 58.4 %
Netherlands
2001 (Children
(1 to 17y) (Aug
to Dec))
Children (1 to 17y)
(Aug to Dec)
610 Yes Self-administered
postal questionnaire
Annual incidence Not reported Yes 75.0 %
Netherlands
2005/2006
(Neonates/
infants (group II))
Neonates/infants
(group II)
359 Yes NA Annual incidence Yes Yes 98.00 %
Netherlands
1996–1998
(Dementia in
nursing homes)
Dementia in nursing
homes
143 Yes Self-administered
questionnaire
Annual incidence No Yes 86.7 %
Belgium
(Flanders)
2007/2008
(NSCLC patients)
NSCLC patients 291 Yes Self-administered
questionnaire
Annual incidence Not reported Yes 91.3 %
Sweden 1998
(Palliative care
physicians)
Palliative care
physicians
122 Yes Self-administered
postal questionnaire
Annual incidence No Yes 83.0 %
Sweden 1998
(Association for
the Study of
Pain Physicians)
Association for the
Study of Pain
Physicians
130 Yes Self-administered
postal questionnaire
Annual incidence No Yes 82.0 %
EUROPE 2005
(RICU patients)
RICU patients 6008 Yes Self-administered
web questionnaire
Annual incidence Yes Yes 21.5 %
New Zealand
2000b
Physicians 693 Yes Self-administered
postal questionnaire
Annual incidence Uncertain Yes 48.0 %
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Table 4 Coefficients of logit regression models for the frequencies of end-of-life practices
1. Withholding or withdrawal
of treatment
2.1 Use of opioids with possible
life shortening effects
2.2 Use of sedatives with possible
life shortening effects
(95 % CI) (95 % CI) (95 % CI)
Variables Coefficients (2.5 % 97.5 %) p Coefficients (2.5 % 97.5 %) p Coefficients (2.5 % 97.5 %) p
Year −0.002 −0.003 −0.002 <0.001 0.044 0.043 0.045 <0.001 0.101 0.098 0.104 <0.001
Survey types
Death certificates (reference)
Physicians 0.94 0.92 0.95 <0.001 0.02 0.01 0.04 0.01 0.58 0.55 0.60 <0.001
Prospective −0.14 −0.16 −0.12 <0.001 −0.17 −0.19 −0.15 <0.001
Jurisdictions
Netherlands (reference)
Australia −0.39 −0.41 −0.37 <0.001 0.59 0.57 0.61 <0.001
Belgium −0.20 −0.33 −0.06 <0.001 0.00 −0.11 0.11 0.98 0.13 −0.04 0.29 0.13
Belgium (Flanders) −0.19 −0.20 −0.17 <0.001 −0.10 −0.11 −0.09 <0.001 0.44 0.42 0.46 <0.001
Denmark −0.34 −0.37 −0.32 <0.001 0.13 0.11 0.15 <0.001 −0.86 −0.92 −0.81 <0.001
France 0.03 0.00 0.05 0.03 −0.09 −0.12 −0.07 <0.001
Italy −1.71 −1.77 −1.64 <0.001 −0.27 −0.31 −0.24 <0.001 0.42 0.37 0.47 <0.001
Sweden −0.34 −0.36 −0.32 <0.001 −0.15 −0.17 −0.13 <0.001 −0.61 −0.65 −0.57 <0.001
Switzerland (German- speaking) 0.53 0.51 0.55 <0.001 −0.09 −0.11 −0.07 <0.001 −0.19 −0.24 −0.14 <0.001
UK 3.28 1.57 4.99 <0.001 −0.41 −0.44 −0.38 <0.001 −204.15 −209.97 −198.32 <0.001
Table 4 Coefficients of logit regression models for the frequencies of end-of-life practices (Continued)
3.1 Intentional use of lethal drugs
self-dministered by patients under
patient request
3.2 Intentional use of lethal drugs,
administered by professionals
under patient request
3.3 Intentional use of lethal drugs
administered by professionals
without patient voluntary request
(95 % CI) (95 % CI) (95 % CI)
Variables Coefficients (2.5 % 97.5 %) p Coefficients (2.5 % 97.5 %) p Coefficients (2.5 % 97.5 %) p
Year −0.049 −0.056 −0.042 <0.001 0.016 0.014 0.018 <0.001 −0.057 −0.061 −0.053 <0.001
Survey types
Death certificates
Physicians 0.25 0.16 0.33 <0.001 0.00 −0.03 0.03 1.00 0.07 0.01 0.12 0.02
Prospective 0.42 0.31 0.54 <0.001 0.29 0.24 0.33 <0.001 0.54 0.48 0.60 <0.001
Jurisdictions
Netherlands
Australia −0.94 −1.13 −0.75 <0.001 −0.18 −0.22 −0.13 <0.001 1.59 1.54 1.65 <0.001
Belgium 1.36 0.97 1.76 <0.001
Belgium (Flanders) −0.17 −0.31 −0.02 0.03 −0.72 −0.77 −0.67 <0.001 1.59 1.55 1.64 <0.001
Denmark −0.94 −1.28 −0.60 <0.001 −3.69 −4.03 −3.35 <0.001 0.29 0.19 0.40 <0.001
France
Italy −15.08 −406.00 375.83 0.94 −4.08 −4.75 −3.42 <0.001 −2.16 −2.71 −1.60 <0.001
Sweden −15.08 −206.02 175.86 0.87 −14.83 −57.44 27.77 0.49 −0.78 −0.92 −0.64 <0.001
Switzerland (German- speaking) 0.86 0.69 1.03 <0.001 −2.18 −2.36 −1.99 <0.001 −0.17 −0.33 −0.02 0.02
UK −15.08 −205.07 174.91 0.87 −2.57 −2.72 −2.42 <0.001 −0.26 −0.40 −0.13 <0.001
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